Product Description
Phentolamine is an alpha-Adrenergic Blocker. Phentolamine is a synthetic imidazoline with alpha-adrenergic antagonist activity. As a competitive alpha-adrenergic antagonist, phentolamine binds to alpha-1 and alpha-2 receptors, resulting in a decrease in peripheral vascular resistance and vasodilatation. This agent also may block 5-hydroxytryptamine (5-HT) receptors and stimulate release of histamine from mast cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Phentolamine)
Mechanisms of Action: ADR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral,Subcutaneous,Transdermal,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | China | Denmark | Egypt | France | Germany | Greece | Ireland | Italy | Korea | Malta | New Zealand | Norway | Portugal | Slovenia | South Africa | Spain | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: Anastesia Related
Known Adverse Events: Pain Unspecified
Company: Ocuphire Pharma
Company Location: FARMINGTON HILLS MI 48335
Company CEO: Mina Sooch
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Mydriasis|Night Blindness|Presbyopia|Vision Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VEGA-3 | P3 |
Recruiting |
Presbyopia |
2025-10-30 |
|
| LYNX-2 | P3 |
Recruiting |
Night Blindness |
2025-09-01 |
|
| VEGA-2 | P3 |
Completed |
Presbyopia |
2023-10-11 |
47% |
| OPI-NYXDLD-301 (LYNX-1) | P3 |
Completed |
Vision Disorders |
2022-05-19 |